Disc Medicine, Inc.
Clinical trials sponsored by Disc Medicine, Inc., explained in plain language.
A clinical-stage biotech developing treatments for hematologic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could let Sun-Sensitive patients enjoy the outdoors Results expected Sep 2026 (estimated) May already have reported ↗
- New hope for IBD patients with anemia: experimental drug enters trial Results expected Oct 2026 (estimated) May already have reported ↗
- New drug aims to reduce Blood-Letting in rare blood cancer Results expected Feb 2027 (estimated) May already have reported ↗
- New drug aims to cut blood transfusions for bone marrow disease patients Results expected May 2027 (estimated) May already have reported ↗
- New sickle cell drug DISC-3405 enters early human safety trial Results expected Jun 2027 (estimated) May already have reported ↗
-
New drug bitopertin offers hope for sunlight pain relief in rare blood disorders
Disease control By invitation onlyThis long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…
Phase 2/3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New pill could let Sun-Sensitive patients enjoy the outdoors
Disease control OngoingThis Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …
Phase 3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug aims to reduce Blood-Letting in rare blood cancer
Disease control OngoingThis study tests an experimental drug called DISC-3405 in 60 adults with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to see if the drug can safely lower the need for phlebotomies (blood removal) and control blood counts. Participants …
Phase 2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC